3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Classical hematology
1
Conditions
Carcinoma, Non-Small-Cell Lung
8
Lymphoma
7
Breast Neoplasms
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Leukemia, Myeloid, Acute
5
Multiple Myeloma
4
Lymphoma, T-Cell, Cutaneous
4
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Mantle-Cell
3
Leukemia
3
Glioblastoma
3
Brain Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Recurrence
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Ovarian Neoplasms
2
Oligodendroglioma
2
Neoplasms
2
Neoplasm Metastasis
2
Myelodysplastic Syndromes
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, T-Cell
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Interventions
eltrombopag
4
Platelet Transfusion
4
romiplostim
2
Cytarabine
2
Cyclophosphamide
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
sodium thiosulfate
1
pegfilgrastim
1
niraparib
1
fludarabine
1
etoposide phosphate
1
Vorinostat
1
Tranexamic Acid
1
Temozolomide
1
Stem Cell Transplantation
1
Saline Solution
1
Rituximab
1
Radiotherapy
1
Pharmacokinetics
1
Hematopoietic Stem Cell Transplantation
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Etoposide
1
Comparative Genomic Hybridization
1
Carboplatin
1
Busulfan
1
Aspirin
1
Amplified Fragment Length Polymorphism Analysis
1
Aminocaproic Acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Thrombocytopenia
×
Vorinostat
×
Clear all
NCT01500538
2016-02-15
VEIL
Peter MacCallum Cancer Centre, Australia
Phase 2
Terminated
1 enrolled